LataMed AI Corp. (OTC: LMED) has provided shareholders with an update on the implementation of its previously announced 5-for-1 forward stock split and mandatory share exchange process. As of July 7, 2026, the Company has submitted all required information to FINRA, and management anticipates the corporate action may become effective within approximately the next week, subject to FINRA's review and final processing. The forward stock split will be accompanied by a new CUSIP number, 21116R404, replacing the current CUSIP to facilitate the mandatory exchange.
Shareholders holding shares through brokerage accounts are generally not required to take any action, as brokerage firms and custodians are expected to process the exchange automatically. Similarly, registered book-entry shareholders holding shares directly with the Company's transfer agent will have their accounts updated automatically to reflect the post-split share balance and new CUSIP. However, physical stock certificate holders are advised that while they are not required to immediately surrender their certificates, existing certificates will represent the pre-exchange security. Upon submission for transfer, sale, or exchange, the transfer agent will process the certificates according to the mandatory exchange procedures and issue post-split shares under the new CUSIP.
Dr. Kevin Rodan Levy, CEO of LataMed AI, emphasized the importance of clear guidance for shareholders, particularly those holding physical certificates. He stated that the Company intends to focus on advancing its telemedicine platform and pursuing licensing and commercialization opportunities for its CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms, which are key components of its long-term strategy to build an integrated digital healthcare ecosystem in Latin America.
The forward stock split is viewed by management as supporting the Company's corporate development and strategic initiatives, while facilitating the implementation of the new CUSIP and updated capital structure. The Company encourages shareholders with questions to contact their brokerage firm or the Company's transfer agent once detailed exchange instructions are available. Additional updates regarding the effective date will be provided as the process progresses.
For more information, visit https://latamed.ai or review the Company's SEC filings at www.sec.gov.
